YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
(RTTNews) - "If you aren't willing to own a stock for 10 years, don't even think about owning it for 10 minutes." - Warren Buffett. The Oracle of Omaha's timeless advice reminds us that patience is one of the key principles of investing. T…
- The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau's ReSTART pivotal trial for recurrent cSCC, which recently completed patient enrollment, under which the Banner MD Anderson team, led by Dr. Sa…
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Alpha Tau Medical Ltd. DRTS is a clinical-stage oncology therapeutics company. The Zacks Consensus Estimate for its current year earnings has been revised 34% downw…
- Following the pre-specified interim safety report and overwhelming demand from clinicians to treat patients as quickly as possible, Alpha Tau to resume recruitment immediately for the remaining seven patients in the trial - - Marks the l…
(RTTNews) - Alpha Tau Medical Ltd. (DRTS), developer of Alpha DaRT platform, and Tolmar International Ltd., announced a strategic collaboration agreement to develop and commercialize Alpha DaRT for prostate cancer treatment in the United S…
(RTTNews) - Today's gainers list includes ABIVAX, which recently announced positive ulcerative colitis trial results; Cingulate, which is working toward resubmission of a New Drug Application for an ADHD therapy; and Alpha Tau, following i…
JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will…
(RTTNews) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning multiple therapeutic areas, including Wilson's Disease, Ovaria…
NEW YORK, NY / ACCESS Newswire / March 18, 2026 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day March Small-Cap Virtual Investor Conference taking place Wedne…
- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment - - M…
H.C. Wainwright analyst Yi Chen raised the firm’s price target on Alpha Tau (DRTS) to $12 from $9 and keeps a Buy rating on the shares after Japan’s Ministry of Health, Labour and Welfare granted marketing approval for Alpha DaRT for the t…
- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in cancers of internal organs including the p…
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Alpha Tau Medical Ltd. DRTS is a clinical-stage oncology therapeutics company. The Zacks Consensus Estimate for its current year earnings has been revised 2% downwa…
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Darling Ingredients DAR is a provider of rendering, cooking oil and bakery waste recycling and recovery solutions. The Zacks Consensus Estimate for its current year…
Mr. Melnyk has more than 30 years of proven experience in oncology commercialization and leadership across pharmaceuticals, medical devices and biotech sectors. PRINCETON, N.J., January 20, 2026--(BUSINESS WIRE)--Taiho Oncology, Inc., a co…
(RTTNews) - Alpha Tau Medical Ltd (DRTS) has submitted the first module of its Pre-Market Approval application to the U.S. FDA for Alpha DaRT, its alpha-radiation therapy designed for patients with recurrent cutaneous squamous cell carcino…
Alpha Tau Medical Ltd. - The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestones - JERUSALEM, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau"…
(RTTNews) - Biotech stocks showed sharp moves in extended trading, with several names rebounding after steep regular-session losses. Fresh clinical data, FDA designations, and financing announcements drove momentum across the sector, highl…
NEW YORK, NY / ACCESS Newswire / December 9, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day Year-End Virtual Investor Conference taking place Wednesday…
(RTTNews) - Alpha Tau Medical Ltd. (DRTS), a clinical-stage oncology company pioneering Alpha DaRT for solid tumors, has several key milestones approaching in the next few months. The company's lead therapeutic platform, Alpha DaRT, is bei…
- Alpha DaRT pancreatic cancer patient treatments underway in U.S. multi-center pilot study - - Newly received radioactive material license for New Hampshire facility positions the Company for continued advancement towards commercial readi…
- Receipt of critical license marks significant milestone for first commercial-scale manufacturing facility for Alpha DaRT®, the innovative alpha-radiation cancer therapy designed for potent and conformal tumor irradiation - -License paves…
– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program – – Study explores Alpha DaRT® combined with chemotherapy in patients with newly diagnosed unresectable locally…
JERUSALEM, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will…
* Alpha Tau Medical press release [https://seekingalpha.com/pr/20196614-alpha-tau-announces-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:DRTS [https://seekingalpha.com/symbol/DRTS]): Q2 GAAP EPS of -$0.22. *…
* Alpha Tau (NASDAQ:DRTS [https://seekingalpha.com/symbol/DRTS]) filed a prospectus to sale 3.46 million ordinary shares. * The company will not receive any proceeds from the sale of ordinary shares by the selling shareholder. * This prosp…
JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will pre…
- Interim data read-out of the first five treated patients demonstrated successful delivery in all five cases, as well as no product-related Serious Adverse Events - - First five patients received conservative partial tumor coverage, and i…
JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and HekaBio K.K. (“HekaBio”) a Japan-based healthcare inve…
- Treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel in September, alongside safety and feasibility trial in similar indication currently underway in Montreal, Canada - - 89% CR, two-y…
JERUSALEM, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will par…
MIAMI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 64th Emerging Growth Conference on November 1st and 2nd, 2023. The Emerging Growth Conference identifies…
MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 64th Emerging Growth Conference on November 1st and 2nd, 2023. The Emerging Growth Conference identifies…
JERUSALEM, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its U.S. subsidiary…
JERUSALEM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Stephen M. Hahn, M.…
MIAMI, Oct. 04, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of Day 2 of the 63rd Emerging Growth Conference on October 5th, 2023. The Emerging Growth Conference identifies…